C

Cannassure Therapeutics Ltd
TASE:CSURE

Watchlist Manager
Cannassure Therapeutics Ltd
TASE:CSURE
Watchlist
Price: 1 720 ILS -9.47% Market Closed
Updated: Jun 2, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

33.8m
-0.7%
Revenue
Dec 31, 2022 33.8m
Dec 31, 2021 34m
Dec 31, 2020 3.5m
-2.8m
+83%
Operating Income
Dec 31, 2022 -2.8m
Dec 31, 2021 -16m
Dec 31, 2020 -28m
-5.5m
+67%
Net Income
Dec 31, 2022 -5.5m
Dec 31, 2021 -16.5m
Dec 31, 2020 -28.5m

Earnings Waterfall
Cannassure Therapeutics Ltd

Revenue
33.8m ILS
Cost of Revenue
-30.5m ILS
Gross Profit
3.3m ILS
Operating Expenses
-6.1m ILS
Operating Income
-2.8m ILS
Other Expenses
-2.7m ILS
Net Income
-5.5m ILS

Income Statement
Cannassure Therapeutics Ltd

Rotate your device to view
Income Statement
Currency: ILS
Dec-2020 Dec-2021 Dec-2022
Revenue
Revenue
3
N/A
34
+873%
34
-1%
Gross Profit
Cost of Revenue
(18)
(41)
(30)
Gross Profit
(14)
N/A
(7)
+52%
3
N/A
Operating Income
Operating Expenses
(14)
(9)
(6)
Selling, General & Administrative
(7)
(6)
(3)
Research & Development
(5)
(2)
(2)
Depreciation & Amortization
(1)
(0)
(0)
Other Operating Expenses
0
0
(0)
Operating Income
(28)
N/A
(16)
+43%
(3)
+83%
Pre-Tax Income
Interest Income Expense
0
(0)
(1)
Non-Reccuring Items
(0)
0
0
Total Other Income
(1)
(1)
(2)
Pre-Tax Income
(29)
N/A
(17)
+42%
(5)
+67%
Net Income
Income from Continuing Operations
(29)
(17)
(5)
Net Income (Common)
(29)
N/A
(17)
+42%
(5)
+67%
EPS (Diluted)
-4.26
N/A
-2
+53%
-0.66
+67%

See Also

Summary
CSURE intrinsic value, competitors valuation, and company profile.
DCF Valuation
CSURE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CSURE stock valuation using valuation multiples.
Wall Street Estimates
CSURE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CSURE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 142,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.